ARHGEF38 as a novel biomarker to predict aggressive prostate cancer  

作　　者：Kun Liu Aixiang Wang Longke Ran Wanfeng Zhang Song Jing Yujing Wang Xianqin Zhang Geli Liu Wang Sen Fangzhou Song 

机构地区：[1]Molecular Medicine and Cancer Research Center,Chongqing Medical University,Chongqing,400016,China [2]Tianjin Key Institute of Urology,Department of Urology,Second Hospital of Tianjin Medical University,300162,Tianjin,China [3]Department of Bioinformatics,Chongqing Medical University,Chongqing,400016,China

出　　处：《Genes & Diseases》2020年第2期217-224,共8页基因与疾病（英文）

基　　金：The study was funded by the Tianjin Medical University Second Hospital Fund(2017ydey06);Chongqing Science and Technology Commission(cstc2018jcyjAX0199)。

摘　　要：Prostate cancer(PCa)metastasis is considered the leading cause of cancer death in males.Therapeutic strategies and diagnosis for stage-specific PCa have not been well understood.Rho guanine nucleotide exchange factor 38(ARHGEF38)is related to tumor cell polarization and is frequently expressed in PCa.Microarray data of PCa were downloaded from GEO and TCGA databases.A total of 243 DEGs were screened,of which,32 genes were upregulated.The results of enrichment analysis showed the participation of these DEGs in the tumor cell metastasis pathway.ARHGEF38 was significantly up-regulated in the four most prevalent cancers worldwide(p<0.05),and its expression was higher in the tumor samples with higher Gleason score(GS).IHC,qRT-PCR,and western-blot analyses showed the higher expression of ARHGEF38 in PCa than benign prostatic hyperplasia(BPH).In addition,IHC results demonstrated a higher expression of ARHGEF38 in high-grade PCa than the low-grade PCa.

关 键 词：Gleason score IMMUNOHISTOCHEMISTRY KaplaneMeier survival PCa 

分 类 号：R737.25[医药卫生—肿瘤]